Cercar
26/10/2023
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
Kwatra, SG, Yosipovitch, G, Legat, FJ, Reich, A, Paul, C, Simon, D, Naldi, L, Lynde, C, De Bruin-Weller, MS, Nahm, WK, Sauder, M, Gharib, R, Barbarot, S, Szepietowski, JC, Conrad, C, Fleischer, A, Laquer, VT, Misery, L, Serra-Baldrich, E, Lapeere, H, Ahmad, F, Lopez, ZKJ, Piketty, C, Ständer, S. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(17)DOI:10.1056/NEJMoa2301333. PMID:37888917. IF:96.300(Q1/1D).
01/10/2023
The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
Rivera-Díaz R, Pozo T, Alfageme F, Díaz Ley B, Osorio GF, Chico R, Vilarrasa E, Silvente C, Ciudad Blanco C, Romaní J, Martorell A, Fernández P, Romero Ferreiro C, Molina Leyva A. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.. Actas Dermo-Sifiliograficas. 2023; 114(9)DOI:10.1016/j.ad.2023.06.018. PMID:37479135. IF:(Q/D).
14/09/2023
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Girolomoni, G, Savage, L, Gisondi, P, Svensson, A, Mahe, E, Augustin, M, Puig, L. Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review. Dermatology and Therapy. 2023; DOI:10.1007/s13555-023-01014. PMID:. IF:3.500(Q1/3D).
01/09/2023
Statins and psoriasis: Position statement by the Psoriasis Task Force of the European Society of Dermatology and Venerology
Gonzalez-Cantero, A, Boehncke, WH, De Sutter, J, Zamorano, JL, Lambert, J, Puig, L. Statins and psoriasis: Position statement by the Psoriasis Task Force of the European Society of Dermatology and Venerology. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(9)DOI:10.1111/jdv.19191. PMID:37259959. IF:8.500(Q1/1D).
01/09/2023
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Berenguer-Ruiz S., Aparicio-Domínguez M., Herranz-Pinto P., Ruíz-Villaverde R., López-Ferrer A., Santos-Juanes J., Rodríguez Fernández-Freire L., Hospital-Gil M., Arias-Santiago S., Carretero-Hernández G., Mateu-Puchades A., Ferran M., del Alcázar E., Santos-Alarcón S., Garcia-Latasa de Aranibar F.J., Belinchón-Romero I., González-Cantero Á., Ruíz-Genao D., Eiris-Salvado N., Rocamora-Durán V., Rivera-Diaz R., de la Cueva P., Daudén E., Salgado-Boquete L., Llamas-Velasco M.. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; DOI:10.1111/jdv.19468. PMID:37625815. IF:8.500(Q1/1D).
01/09/2023
Epidermolysis bullosa acquisita induced by atezolizumab
Carmona-Rocha E., Aguado M., Tubau C., Sánchez S., Mozos A., Sullivan I., Spertino J.. Epidermolysis bullosa acquisita induced by atezolizumab. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2023; DOI:10.1111/ddg.15203. PMID:37658659. IF:5.600(Q1/1D).
23/08/2023
Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium
Carmona-Rocha, E, Puig, L. Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium. Immunotherapy. 2023; 15(15)DOI:10.2217/imt-2023-0013. PMID:37609785. IF:2.700(Q3/7D).
23/08/2023
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA)
Pereyra-Rodríguez J.J., Poveda J.L., Rivero A., Serra-Baldrich E., Silvestre J.F., Armario-Hita J.C., Calleja M.Á., Carrascosa J.M., Flórez Á., Herranz P., Comellas M., Ortiz de Frutos F.J.. Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA). JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; DOI:10.1111/jdv.19432. PMID:37594914. IF:8.500(Q1/1D).